Risk factor
Very poor trading liquidity
Profitability factor
Strong growth
About
C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solution for patient set up and intra-fraction breath hold reproducibility; Catalyst+ PT, a surface image guided radiation therapy solution that supports proton therapy from simulation to treatment; Catalyst+ HD Ring Gantry solution for patient positioning, real-time motion monitoring, and respiratory gating; and Sentinel 4DCT, a laser-based optical surface scanning system. It also provides Catalyst, a 4D surface guided radiation therapy (SGRT) solution; Catalyst HD, a SGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; Catalyst PT, a tracking solution for particle therapy; and visual coaching solutions used for prospective and retrospective radiotherapy. In addition, the company offers cAutoVerify, an automation solution for the imaging suite and treatment room, automating patient identity validation, and accessory tracking; and cAccessory, which automates the registration and validation of treatment accessories. Further, it provides SmartPhantom RT, a device that allows automatic adjustment and alignment of fixed lasers with motorization; StaticPhantom, a set-up used to visually verify the precision of the alignment of lasers; high impact technology motorized system, a laser positioning system; HIT Single Diode; and HIT1, HIT3, and HIT5 patient positioning laser, as well as laser positioning products and solutions. Additionally, the company offers support and training services; and service contracts. C-Rad AB (publ) was incorporated in 2004 and is headquartered in Uppsala, Sweden.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair value on
Target Price
The average target price of CRAD-B.ST is 45.0 and suggests 21.3% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to